CD274 and cancer: Immune checkpoint blockade (ICB) therapies such as anti-PD-1/anti-PD-L1 have dramatically improved outcomes in patients with melanoma, non-small cell lung cancer, and other tumor types, making them one of the most promising therapies in the field of cancer treatment.